EST Pharm’s Executive Vice President, Choi Seok-woo, stated the company intends to become a core partner in the next generation of RNA therapeutics market. Speaking from San Diego, Choi highlighted EST Pharm’s manufacturing capabilities as the foundation for its ambitions in RNA therapy development. The company aims to leverage its expertise to support the advancement of these novel treatments. EST Pharm’s strategy focuses on providing crucial manufacturing support to companies innovating in the RNA space. This move positions EST Pharm to capitalize on the growing demand for RNA-based therapies. The company believes its robust manufacturing infrastructure will be a key asset in bringing these therapies to market.